This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.Study Design: Phase II/II, randomized, multicenter, double-masked, placebo-controlled studyStudy Objectives: The purpose to this study is to learn about how safe and effective rituximab will be for people diagnosed with ANCA-associated vasculitis (AAV)Study Medication: Rituximab (Rituxan) Number of Subjects: 200Number of Centers: 9 (US and Europe) AAV is a severe autoimmune disorder that leads to inflammation within the blood vessels. The cause of AAV is unknown. Patients with AAV have problems with their immune system. Rituximab works by decreasing the immune cells in the body that may have a role in AAV. Once those cells are removed, the body will make new cells. This study will also help to learn if the new immune cells will not cause the disease to come back. Participants will be randomized 1:1 to either the control or the experimental arm. Participants will remain in the study until the last participant enrolled completes all required study visits, which will take at least 18 months.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
2M01RR000533-39
Application #
7606255
Study Section
National Center for Research Resources Initial Review Group (RIRG)
Project Start
2007-01-03
Project End
2007-11-30
Budget Start
2007-01-03
Budget End
2007-11-30
Support Year
39
Fiscal Year
2007
Total Cost
$66,779
Indirect Cost
Name
Boston University
Department
Administration
Type
Schools of Medicine
DUNS #
604483045
City
Boston
State
MA
Country
United States
Zip Code
02118
Christensen, Kurt D; Roberts, J Scott; Whitehouse, Peter J et al. (2016) Disclosing Pleiotropic Effects During Genetic Risk Assessment for Alzheimer Disease: A Randomized Trial. Ann Intern Med 164:155-63
Richardson, Mark A; Grant-Knight, Wanda; Beeghly, Marjorie et al. (2016) Psychological Distress Among School-Aged Children with and Without Intrauterine Cocaine Exposure: Perinatal Versus Contextual Effects. J Abnorm Child Psychol 44:547-60
Barthelemy, Olivier J; Richardson, Mark A; Cabral, Howard J et al. (2016) Prenatal, perinatal, and adolescent exposure to marijuana: Relationships with aggressive behavior. Neurotoxicol Teratol :
Barthelemy, Olivier J; Richardson, Mark A; Rose-Jacobs, Ruth et al. (2016) Effects of intrauterine substance and postnatal violence exposure on aggression in children. Aggress Behav 42:209-21
Gruchalla, R S; Sampson, H A; Liu, A H et al. (2016) Effects of omalizumab on T lymphocyte function in inner-city children with asthma. Pediatr Allergy Immunol 27:328-31
Unizony, Sebastian; Villarreal, Miguel; Miloslavsky, Eli M et al. (2016) Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Ann Rheum Dis 75:1166-9
Unizony, Sebastian; Lim, Noha; Phippard, Deborah J et al. (2015) Peripheral CD5+ B cells in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol 67:535-44
Green, Robert C; Christensen, Kurt D; Cupples, L Adrienne et al. (2015) A randomized noninferiority trial of condensed protocols for genetic risk disclosure of Alzheimer's disease. Alzheimers Dement 11:1222-30
Christensen, Kurt D; Roberts, J Scott; Zikmund-Fisher, Brian J et al. (2015) Associations between self-referral and health behavior responses to genetic risk information. Genome Med 7:10
Tager-Flusberg, Helen (2015) Defining language impairments in a subgroup of children with autism spectrum disorder. Sci China Life Sci 58:1044-52

Showing the most recent 10 out of 461 publications